Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CD69 | Q07108 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743332 | 0.90 | POLB (0.62) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL31552456 | 0.89 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL6745272 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL7824239 | 0.88 | KDM4E (0.60) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL18702949 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL1145948 | 0.86 | KMT2A (0.62) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL6449648 | 0.85 | POLB (0.57) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL9774310 | 0.85 | POLB (0.57) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL2554736 | 0.85 | PTGDR2 (0.62) | SMN1; SMN2POLBKMT2ALMNACD69 | |
| SCHEMBL13665131 | 0.84 | HPGD (0.63) | SMN1; SMN2POLBALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349244-B | Benzimidazole and quinazoline dimethoxy-benzene oxygen acetyl-AA-OBzl, synthesis, activity and application | 首都医科大学 | 2018-07-27 | — | — | CN | disclosed |
| CN-106349244-A | Benzo imidazo quinazoline dimethyl oxygen benzene oxygen acetyl-AA-OBzl, as well as synthesis, activity and application thereof | 首都医科大学 | 2017-01-25 | — | — | CN | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0750614-B1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI CHEM PHARM (CH) | 2001-05-23 | — | — | EP | disclosed |
| US-5798362-A | USEFUL AS ALPHA-ADRENORECEPTOR BLOCKERS; CONDENSATION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-08-25 | — | — | US | disclosed |
| EP-0750614-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025726-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-09-28 | — | — | WO | disclosed |
| EP-0244723-A2 | Benzothiazinone derivatives, process for their preparation, medicaments containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | SMN1; SMN2 3669/4885POLB 632/4885ALDH1A1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.